Application of peripheral blood mononuclear cell subpopulation in predicting prognosis of liver transplantation patient
By detecting the characteristic changes of peripheral blood mononuclear cell subpopulations, especially the ratio and surface molecular expression changes of Mo0, Mo1, Mo2 and Mo3 subpopulations, the problem of predicting postoperative immune status changes and prognosis in patients with liver transplantation is solved. Accurate prediction of the 90-day survival rate of liver transplant patients is achieved, providing a simple and fast detection method.
Patent Information
- Application Number
- CN202411090307.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-07
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively predict the postoperative immune status changes and prognosis of patients with liver transplantation, and there is a lack of accurate biomarkers to evaluate and predict the 90-day survival rate of patients with liver transplantation.
By detecting the characteristic changes of peripheral blood mononuclear cell subpopulations, especially the ratio and surface molecular expression changes of Mo0, Mo1, Mo2 and Mo3 subpopulations, combined with cell flow technology and mass spectrometry flow technology, predictive liver transplant patients were prepared and predicted. Prognostic product.
The overall immune status of patients is achieved through the changes in monocyte activation rate, and the 90-day survival rate of liver transplant patients is predicted, providing a simple and fast detection method with high efficiency and correlation.
Smart Images

Figure CN118962153A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of peripheral blood monocyte subsets in predicting the prognosis of liver transplant patients, and in particular to the application of reagents for detecting characteristic changes in peripheral blood monocyte subsets in preparing products for predicting the prognosis of liver transplant patients. Background Art
[0002] Allogeneic orthotopic liver transplantation is an effective treatment for end-stage liver disease, but changes in immune status after liver transplantation are an important factor affecting graft function. Therefore, finding appropriate clinical indicators to evaluate and predict changes in immune status after transplantation is one of the research hotspots. Monocytes are one of the important members of the innate immune system. They account for about 5%-10% of the peripheral blood and include three common subpopulations, namely, classical monocytes Mo1:CD14 + CD16 - HLA-DR low (85%-90%), intermediate monocytes Mo2: CD14 + CD16 hi HLA-DR hi (5%-10%) and non-classical monocytes Mo3:CD14 + CD16 hi HLA-DR + (The proportion is 5%-10%). However, the classification of monocytes is still under debate, and surface marker molecules that define new subpopulations are constantly being discovered. Some studies have used mass spectrometry to define the classification of monocyte subpopulations.
[0003] In addition to the classification and definition of its subpopulations, the heterogeneity of monocytes is also reflected in the different immune functions of cells in different subpopulations. The expression levels of different immune function molecules, such as antigen presentation function, signal transduction function, chemotaxis function and phagocytosis function, vary in different immune microenvironments or disease states. Among them, the continuous decrease in HLA-DR expression on the surface of monocytes is a classic sign of immunosuppression. At the same time, changes in HLA-DR expression can predict the clinical prognosis of patients with liver failure, that is, the expression level of HLA-DR on monocytes gradually returns to normal levels in patients with good prognosis.
[0004] A more immature monocyte subset CD14 is present in the peripheral blood of patients with severe infection, extracorporeal circulation (CPB) and ECMO. low CD16 - HLADR low(Mo0), the proportion of this group varies greatly, and they also have the ability to differentiate into other monocyte subsets. In the mouse model experiment of extracorporeal circulation, it was confirmed that Mo0 may be one of the causes of acute lung injury after CPB. This study believes that the appearance of Mo0 is a signal of the patient's condition change. In addition, the increase in the proportion of non-classical monocytes in patients with IgA nephropathy suggests that they can indirectly reflect the immune status of the disease process. Reports have confirmed that the proportion of monocyte subsets in the peripheral blood of renal transplant patients is correlated with changes in their immune status, that is, CD16, which has a strong ability to secrete proinflammatory cytokines TNF-α, IL-1β and IFN-γ hi HLA-DR + The increase in the proportion of monocyte subsets may be one of the driving factors for the cellular immune response after renal transplantation. Compared with healthy controls, HLA-DR + An increase in the proportion of monocytes indicates that the body is in an immune activation state. Therefore, monitoring the changes in the proportion of monocyte subsets and cytokine secretion levels can be used as one of the indicators to predict graft loss after renal transplantation.
[0005] In addition, in lung transplant patients and mouse models, it was found that monocytes expressed CXCR3 and CXCL2 and upregulated the MyD88 signaling pathway to attract neutrophils into the graft, causing graft damage. Through gene knockout models, it was found that monocyte CXCR3 or CXCL2 expression defects can reduce neutrophil chemotaxis to the graft. Studies have shown that CCR2 is a potential therapeutic target for alleviating autoimmune reactions after lung transplantation by regulating the recruitment of monocytes and the recognition of Th1 lymphocytes. In patients with chronic graft-versus-host disease after hematopoietic stem cell transplantation, the proportion of monocyte subsets in affected organs showed an increasing trend and was positively correlated with the global NIH score. Since the current view is that monocytes are less affected by immunosuppressive drugs, this study believes that monocytes can be used as biomarkers for studying chronic graft-versus-host disease. Summary of the invention
[0006] The purpose of the present invention is to propose the application of peripheral blood monocyte subpopulations as biomarkers in predicting the prognosis of liver transplant patients. The characteristic changes of monocyte subpopulations in the peripheral blood of immunosuppressed patients after surgery lead to changes in monocyte activation rate, which can be used as biomarkers for predicting the 90-day clinical prognosis of liver transplant patients. In particular, reagents for detecting characteristic changes of peripheral blood monocyte subpopulations are used to prepare products for predicting the prognosis of liver transplant patients.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] The present invention provides the use of peripheral blood monocyte subpopulations as biomarkers in the preparation of products for predicting the prognosis of liver transplant patients, wherein the monocyte subpopulations are selected from one or more of monocyte subpopulations Mo0, Mo1, Mo2 and Mo3, wherein the monocyte subpopulations Mo0, Mo1, Mo2 and Mo3 are CD14 low CD16 - HLADR low 、CD14 + CD16 - HLA-DR low 、CD14 + CD16 hi HLA-DR hi 、CD14 + CD16 hi HLA-DR + .
[0009] Preferably, the monocyte subpopulation is monocyte subpopulation Mo0, i.e. CD14 low CD16 - HLADR low , as a biomarker for predicting the prognosis of liver transplant patients.
[0010] The present invention also provides the use of a reagent for detecting characteristic changes in peripheral blood monocyte subpopulations in the preparation of a product for predicting the prognosis of a liver transplant patient, wherein the monocyte subpopulation is selected from one or more of monocyte subpopulations Mo0, Mo1, Mo2 and Mo3, wherein the monocyte subpopulations Mo0, Mo1, Mo2 and Mo3 are CD14 low CD16 - HLADR low 、CD14 + CD16 - HLA-DR low 、CD14 + CD16 hi HLA-DR hi 、CD14 + CD16 hi HLA-DR + .
[0011] Preferably, the monocyte subpopulation is monocyte subpopulation Mo0, i.e. CD14 low CD16 - HLADR low , the characteristic change of the monocyte subset is an increase in the proportion of Mo0.
[0012] More preferably, the difference (Δ) in monocyte activation rate of liver transplant patients is correlated with the 90-day survival rate.
[0013] More preferably, the expression level of CD163 in Mo0 is increased, and the expression levels of CCR5, HLA-DR, CD32, CD36, CD86, CD163, Tigit and CX3CR1 in Mo0 are decreased.
[0014] Preferably, the monocyte subpopulations are monocyte subpopulations Mo0 and Mo1, that is, the proportion of Mo0 increases, while the proportion of Mo1 decreases.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] 1. As one of the important innate immune cells, monocytes have the potential to express a variety of surface molecules with different immune functions in different diseases or immune microenvironments, such as CCR2, CCR5, CD11c, CD32, CD64, CD36, CD86, CD163, Tigit, ICAM1 and CX3CR1. The present invention analyzes the changes in the expression of surface molecules such as the chemotaxis and inflammatory state of monocytes and immunosuppressive signal checkpoints to infer the characteristic changes of monocyte subpopulations and combines other immune cells and cytokines and other indicators to comprehensively judge the ongoing response of the body's overall immune state and the reaction process of immune remodeling, and can predict the 90-day survival rate of liver transplant patients after surgery.
[0017] 2. The present invention detects the activation rate of peripheral blood monocytes on the first day and the seventh day after liver transplantation, and calculates that the change in the difference is caused by the characteristic changes in the peripheral blood monocyte subpopulations, that is, the increase in the proportion of Mo0 is one of the reasons for the difference in monocyte activation rate. At the same time, the change in the difference is correlated with the postoperative immune status of liver transplant patients and their 90-day survival rate after liver transplantation. The characteristic changes in peripheral blood monocyte subpopulations can be used as one of the predictive indicators for evaluating the changes in immune status after liver transplantation and the 90-day survival rate of patients. In addition, the present invention can be completed through the extensive clinical use of cell flow cytometry and simple antibody staining, which is simple, fast and has high detection efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The ratios of the four monocyte subsets in the peripheral blood of normal subjects (a) and liver transplant patients (b, c, d) at different time points in the example.
[0019] Figure 2The following are 20 different types of immune cells (a) annotated by TSNE clustering of mononuclear cells isolated from peripheral blood of 10 patients undergoing liver transplantation before and 7 days after liver transplantation in the example, the changes in the proportions of four monocyte subsets (b, c) and the correlation between the 20 different types of immune cells (d); red squares indicate positive correlation, while blue squares indicate negative correlation, and * indicates that the correlation between the two types of immune cells is statistically significant (P<0.05).
[0020] Figure 3 The following are the changes in the expression of surface molecules with different immune functions on the surfaces of four monocyte subsets Mo0, Mo1, Mo2 and Mo3 in the peripheral blood of 10 patients who received liver transplantation before and 7 days after liver transplantation in the example.
[0021] Figure 4 The figures show the correlation between HLA-DR and other immune function molecules on the surface of four monocyte subsets Mo0 (a), Mo1 (b), Mo2 (c) and Mo3 (d) in the peripheral blood of 10 liver transplant patients before and 7 days after liver transplantation in the example.
[0022] Figure 5 : is the ROC curve of the difference in monocyte activation rate and the 90-day survival rate of liver transplant patients in the embodiment. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0024] Example 1
[0025] 1.1. General data From September 2020 to July 2023, a total of 139 patients who underwent allogeneic orthotopic liver transplantation in the Department of Liver Surgery of Zhongshan Hospital Affiliated to Fudan University were enrolled; inclusion criteria included: 1) age older than 18 years; younger than 75 years; 2) DCD liver transplant patients; 3) receiving one liver transplant or the second liver transplant; Exclusion criteria 1): age younger than 18 years and older than 75 years; 2) living donor liver transplant patients; 3) patients who died within 24 hours after surgery; 4) patients who received a third liver transplant; 5) patients with missing data; 6) patients with missing data; All donor livers were derived from the Chinese Human Organ Allocation and Sharing Computer System.
[0026] 1.2. Data collection included patient baseline information and clinical biochemical indicators on the day of surgery, postoperative day 1 (POD1), and postoperative day 7 (POD7): routine blood tests, liver and kidney function, electrolytes, coagulation indicators, C-reactive protein, procalcitonin, cellular immunity such as B lymphocytes, T lymphocytes, NK cells, and pro-inflammatory and anti-inflammatory cytokines such as TNF-α, IL-1β, IL-2R, IL-6, IL-8, and IL-10.
[0027] 1.3 Test methods
[0028] 1) Detection of monocyte activation rate by cell flow cytometry: Take 200uL whole blood, add 1× red blood cell lysis buffer at a ratio of 1:10, shake, and let stand for 10min. After centrifugation at room temperature, discard the supernatant, add 1× phosphate buffer, shake, centrifuge at room temperature and discard the supernatant, add antibodies CD14 FITC and HLA-DR PerCP, incubate at 4℃ in the dark for 20min, add rinsing buffer and shake, centrifuge at room temperature and discard the supernatant, flick the cell pellet, add an appropriate amount of 1× phosphate buffer, and detect on a flow cytometer. The expression of HLA-DR is expressed by mean fluorescence intensity (MFI), and the data are analyzed and exported by Flowjo software.
[0029] 2) Detect the changes in the proportion of each monocyte subpopulation and the expression of functional molecules by mass spectrometry: PBMCs in the peripheral blood of 10 liver transplant patients were detected before and 7 days after surgery. The monocytes were divided into 4 subpopulations by TNSE clustering: Mo0: CD14 low CD16 - HLADR low 、Mo1:CD14 + CD16 - HLADR low 、Mo2:CD14 + CD16 hi HLADR hi and Mo3:CD14 + CD16 hi HLADR + , detect the changes in the expression levels of different immune functional molecules on the surface of these four subpopulations.
[0030] 1.4 Clinical observation endpoints Based on the flow cytometry results of peripheral blood mononuclear cells of the liver transplant patients and the difference in monocyte activation rate (Δ), the liver transplant patients were divided into a Δ>0 group and a Δ<0 group. The correlation between the difference (Δ) and the patient's disease outcome was observed and the clinical characteristics of the two groups of patients were summarized.
[0031] 1.5. SPSS software was used for statistical analysis: normally distributed quantitative data were expressed as x±s, non-normally distributed data were described by the median method, and count data were described by numerical values or percentages. Normally distributed quantitative data were analyzed using t-test and one-way analysis of variance, non-normally distributed data were analyzed using rank sum test, and count data were analyzed using chi-square test. P < 0.05 was considered statistically significant.
[0032] result
[0033] 1. General information, etiology, and number and proportion of liver transplant patients who lost graft function within 90 days after surgery. From September 2020 to July 2023, we enrolled a total of 139 liver transplant patients with a median age of 55 years, of which 107 (76.9%) were males; the causes of the enrolled patients included 68 cases of primary liver cancer (48.9%), 6 cases of primary cholangiocarcinoma (4.3%), 34 cases of decompensated post-hepatitis cirrhosis (24.5%), 8 cases of autoimmune liver disease (5.8%), 7 cases of alcoholic cirrhosis (5%), 1 case of schistosomiasis cirrhosis (0.7%), 2 cases of polycystic liver (1.4%), 10 cases of acute or acute-on-chronic liver failure (7 / 342), graft failure after liver transplantation (7 / 342), and 1 other case (0.7%); the median preoperative MELD score of these patients was 15 points; ultimately, 8 (5.8%) of the 139 liver transplant patients lost graft function within 90 days (Table 1).
[0034] Table 1
[0035]
[0036]
[0037] 2. If Figure 1 As shown in Figure 2, the ratio of normal human peripheral blood monocyte subsets is Mo1:CD14 + CD16 - HLA-DR low 、Mo2:CD14 + CD16 hi HLA-DR hi and Mo3:CD14 + CD16 hi HLA-DR + ; and Mo0:CD14 low CD16 - HLA-DR low The proportion is very small, about 1%-2% ( Figure 1a); The changes in the monocyte subsets in the peripheral blood of patients within 7 days after liver transplantation were mainly characterized by a significant increase in the proportion of newly formed Mo0 and a decrease in the proportion of Mo1. As the clinical outcome of the patients changed, it was observed that the proportion of monocyte subsets gradually tended to the proportion pattern of the normal control group ( Figure 1 bd). It can be seen that compared with normal people, the proportion of monocyte subsets in the peripheral blood of liver transplant patients on the 7th day after surgery (POD7) showed specific changes, that is, the proportion of Mo0 increased ( Figure 1 ).
[0038] like Figure 2 As shown in the figure, mononuclear cells from peripheral blood of 10 liver transplant patients were detected by mass spectrometry flow cytometry and TSNE clustering was used to obtain the classification of four monocyte subpopulations ( Figure 2 a), and verified that the change trend of the proportion of Mo0 in the peripheral blood of the two groups of patients before surgery (Pre-transplant) and 7 days after surgery (Post-transplant) was consistent with the results of flow cytometry, that is, the proportion of Mo0 increased, and the difference was statistically significant (P<0.05), while the proportion of Mo1 decreased significantly, and the difference was statistically significant (P<0.05). There was no statistically significant difference in the proportion of the two monocyte subsets Mo2 and Mo3 with high HLA-DR expression ( Figure 2 b) In addition, there is a correlation between Mo0 and other TNSE-clustered immune cells, such as CD4 + Treg and switched-memory B lymphocytes. In addition, there was a positive correlation between Mo1 and Mo3, and the correlation was also statistically significant (P<0.05, Figure 2 c).
[0039] 3. If Figure 3As shown in the figure, mononuclear cells isolated from peripheral blood of 10 patients who received allogeneic orthotopic liver transplantation before and on the 7th day after liver transplantation were analyzed by mass spectrometry flow cytometry to analyze the changes in the expression of surface molecules with different immune functions such as CCR5, HLA-DR, CD32, CD36, CD86, CD163, Tigit and CX3CR1 on the 7th day after liver transplantation (POD7) in the peripheral blood of patients with different immune functions, including 4 monocyte subsets Mo0, Mo1, Mo2 and Mo3. *Suggesting that the correlation between the two types of immune cells was statistically significant (P<0.05). Mass spectrometry flow cytometry experiments showed that compared with before liver transplantation, the expression of surface molecules with different immune functions such as CCR5, HLA-DR, CD32, CD36, CD86, CD163, Tigit and CX3CR1 in the peripheral blood of patients with different immune functions, including 4 monocyte subsets Mo0, Mo1, Mo2 and Mo3 on the 7th day after liver transplantation (POD7), were changed. Except for the significantly increased expression of CD163 on Mo0, the expression of CCR5, HLA-DR, CD32, CD36, CD86, CD163, Tigit and CX3CR1 on Mo0 was significantly downregulated, and the difference was statistically significant (P<0.05), while only the difference in the expression of CD163, CCR5, CD32, CD36 and CD86 on Mo1 was statistically significant (P<0.05). Although there was no statistically significant difference in the expression of HLA-DR on the surface of Mo1 and Mo3; however, the expression of HLA-DR on the surface of Mo2 was significantly downregulated, and the difference was statistically significant (P<0.05) ( Figure 3 ).
[0040] like Figure 4 As shown, mononuclear cells isolated from peripheral blood of 10 patients who received allogeneic orthotopic liver transplantation before and on the 7th day after liver transplantation were analyzed by mass spectrometry technology. The correlation between HLA-DR and other immune function molecules on the surface of four monocyte subsets Mo0 (a), Mo1 (b), Mo2 (c) and Mo3 (d) in the peripheral blood of patients on the 7th day after liver transplantation (POD7) was analyzed. *Suggested that the correlation between the two types of immune cells was statistically significant (P<0.05). The expression of HLA-DR on the surface of Mo0 was positively correlated with the expression of inhibitory signal transduction molecules (Tigit and PD1), chemotaxis function (CCR2 and ICAM1), pro-inflammatory molecules (CD49d) and antigen presentation molecules (CD86 and CD40), and the correlation between them was statistically significant (P<0.05) ( Figure 4 ).
[0041] 4. Evaluation of CD14 in peripheral blood of liver transplant patients on postoperative day 1 (POD1) and postoperative day 7 (POD7) by flow cytometry +The monocyte activation rate was calculated and the difference between the two results (Δ) was calculated. According to the results, the patients were divided into two groups: Δ>0 group (73 cases) and Δ<0 group (66 cases). By comparing the biochemical examination indicators of the two groups, it was found that the differences in PT, PCT and the number of days of hospitalization in the ICU between the Δ>0 group and the Δ<0 group were statistically significant (P<0.05), although the difference in the positive rate of traditional pathogen culture was not statistically significant (P=0.1267). In addition, there was no statistically significant difference in the preoperative MELD score between the two groups (P=0.4517) (Tables 2 and 3).
[0042] Table 2: Biochemical examination indicators of patients with different trends in peripheral blood monocyte activation rate
[0043]
[0044]
[0045] Note: Wbc: white blood cell; Tb: total bilirubin; ALT: alanine aminotransferase; PT: prothrombin; PCT: procalcitonin; Cr: creatinine.
[0046] Table 3: Comparison of infection incidence, hospital stay and ICU stay between the two groups
[0047] D<0 Δ>0 P-value Hospitalization days (days) 25 27 0.803 ICU hospital stay (days) 18 14 0.0181 Number of patients with culture-positive evidence (%) 31 / 66 25 / 73 0.1267
[0048] 5. Comparison of immune cells and cytokines in peripheral blood between the two groups of patients (73 cases in the group with monocyte activation rate difference Δ>0) and the group (66 cases in the group with Δ<0) showed that there was no statistical difference in the absolute number of B lymphocytes, T lymphocytes and NK cells in the peripheral blood between the two groups of patients on the first day after surgery and on the seventh day after surgery. Among the six cytokines, the levels of IL-6 and IL-10, which are mainly secreted by monocytes, were significantly different in the peripheral blood between the two groups of patients on POD7 (P<0.05) (Table 4).
[0049] Table 4: Changes of 6 cytokines between the two groups
[0050]
[0051] 6. The difference (Δ) in monocyte activation rate of liver transplant patients was correlated with the 90-day survival rate of patients, with the area under the ROC curve being 70.8%, the sensitivity being 89.93%, and the specificity being 47.48% ( Figure 5 ).
[0052] The above is a preferred embodiment of the present invention, but the present invention should not be limited to the contents disclosed in the embodiment. Therefore, any equivalent or modification completed without departing from the spirit disclosed in the present invention shall fall within the scope of protection of the present invention.
Claims
1. Use of peripheral blood monocyte subsets as biomarkers in the preparation of products for predicting the prognosis of liver transplant patients, wherein the monocyte subsets are selected from one or more of the monocyte subsets Mo0, Mo1, Mo2 and Mo3, wherein the monocyte subsets Mo0, Mo1, Mo2 and Mo3 are CD14 low CD16 - HLADR low 、CD14 + CD16 - HLA-DR low 、CD14 + CD16 hi HLA-DR hi 、CD14 + CD16 hi HLA-DR + .
2. The use according to claim 1, It is characterized in that The monocyte subpopulation is monocyte subpopulation Mo0, which is used as a biomarker for predicting the prognosis of liver transplant patients.
3. Application of reagents for detecting characteristic changes in peripheral blood monocyte subsets in the preparation of products for predicting the prognosis of liver transplant patients, It is characterized in that The monocyte subpopulation is selected from one or more of the monocyte subpopulations Mo0, Mo1, Mo2 and Mo3, wherein the monocyte subpopulations Mo0, Mo1, Mo2 and Mo3 are CD14 low CD16 - HLADR low 、CD14 + CD16 - HLA-DR low 、CD14 + CD16 hi HLA-DR hi 、CD14 + CD16 hi HLA-DR + .
4. The use according to claim 3, It is characterized in that The monocyte subpopulation is the monocyte subpopulation Mo0, and the characteristic change of the monocyte subpopulation is that the proportion of Mo0 increases.
5. The use according to claim 4, It is characterized in that The expression level of CD163 increased in Mo0, while the expression levels of CCR5, HLA-DR, CD32, CD36, CD86, CD163, Tigit and CX3CR1 decreased in Mo0.
6. The use according to claim 3, It is characterized in that The monocyte subpopulations are monocyte subpopulations Mo0 and Mo1, wherein the proportion of Mo0 increases, while the proportion of Mo1 decreases.
7. The use according to claim 3, It is characterized in that The difference in monocyte activation rate of the liver transplant patients is correlated with the 90-day survival rate.
